9
Participants
Start Date
October 30, 2022
Primary Completion Date
October 30, 2024
Study Completion Date
October 30, 2024
Ibogaine Hydrochloride
The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Ribeirão Preto Medical School, Ribeirão Preto
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
OTHER_GOV
Conselho Nacional de Desenvolvimento Científico e Tecnológico
OTHER_GOV
International Center for Ethnobotanical Education, Research, and Service
OTHER
University of Sao Paulo
OTHER